Berger, J.R., Aksamit, A.J., Clifford, D.B., Davis, L., Koralnik, I.J., Sejvar, J.J., Bartt, R., Major, E.O. & Nath, A. (2013) PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology, 80, 1430–1438. Carson, K.R., Evens, A.M., Richey, E.A., Habermann, T.M., Focosi, D., Seymour, J.F., Laubach, J., Bawn, S.D., Gordon, L.I., Winter, J.N., Furman, R.R., Vose, J.M., Zelenetz, A.D., Mamtani, R., Raisch, D.W., Dorshimer, G.W., Rosen, S.T., Muro, K., Gottardi-Littell, N.R., Talley, R.L., Sartor, O., Green, D., Major, E.O. & Bennett, C.L. (2009a) Progressive multifocal leukoencephalopathy after rituximab therapy in HIVnegative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood, 113, 4834–4840. Carson, K.R., Focosi, D., Major, E.O., Petrini, M., Richey, E.A., West, D.P. & Bennett, C.L. (2009b) Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncology, 10, 816–824. Carson, K.R., Newsome, S.D., Kim, E.J., WagnerJohnston, N.D., von Geldern, G., Moskowitz, C.H., Moskowitz, A.J., Rook, A.H., Jalan, P., Loren, A.W., Landsburg, D., Coyne, T., Tsai, D., Raisch, D.W., Norris, L.B., Bookstaver, P.B., Sartor, O. & Bennett, C.L. (2014) Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer, 120, 2464–2471. Gonzalez, H., Bolgert, F., Dampro, P. & Leblond, V. (1999) Progressive multifocal leukoencephalitis (PML) in three patients treated with standard-dose fludarabine (FAMP). Hematology and Cell Therapy, 41, 183–186. Maddocks, K.J., Ruppert, A.S., Lozanski, G., Heerema, N.A., Zhao, W., Abruzzo, L., Lozanski, A., Davis, M., Gordon, A., Smith, L.L., Mantel, R., Jones, J.A., Flynn, J.M., Jaglowski, S.M., Andritsos, L.A., Awan, F., Blum, K.A., Grever, M.R., Johnson, A.J., Byrd, J.C. & Woyach, J.A. (2015) Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. Journal of the American Medical Association Oncology, 1, 80–87. Teramoto, T., Kaneko, H., Funato, M., Sawa, H., Nagashima, K., Hirose, Y. & Kondo, N. (2003) Progressive multifocal leukoencephalopathy in a patient with X-linked agammaglobulinemia. Scandinavian Journal of Infectious Diseases, 35, 909–910.
[1]
Anna L. Brown,et al.
Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies.
,
2016,
Blood.
[2]
M. Nørgaard,et al.
Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.
,
2015,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3]
B. Ebert,et al.
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.
,
2015,
Blood.
[4]
David A. Williams,et al.
Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy
,
2015,
Nature Genetics.
[5]
Christian Bastard,et al.
TET2 and DNMT3A mutations in human T-cell lymphoma.
,
2012,
The New England journal of medicine.
[6]
C. Pascutto,et al.
Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients
,
2011,
Haematologica.
[7]
E. Sloand.
Myelodysplastic syndromes: introduction.
,
2008,
Seminars in hematology.
[8]
N. Speck,et al.
Runx1 deficiency predisposes mice to T-lymphoblastic lymphoma.
,
2004,
Blood.
[9]
John M Bennett,et al.
Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients.
,
2003,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10]
J. Bennett,et al.
Myelodysplastic syndromes: introduction.
,
2001
.